Defibrotide
Defitelio (defibrotide) is an oligonucleotide pharmaceutical. Defibrotide was first approved as Defitelio on 2013-10-18. It is used to treat hepatic veno-occlusive disease in the USA. It has been approved in Europe to treat hepatic veno-occlusive disease. Defitelio's patent is valid until 2032-06-22 (FDA).
| Trade Name | Defitelio |
|---|---|
| Common Name | Defibrotide |
| Indication | hepatic veno-occlusive disease |
| Drug Class |
